This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ohta, J.-i. Articles by Kubota, Y. Search for Related Content PubMed PubMed Citation Articles by Ohta, J.-i. Articles by Kubota, Y.

Fluorescence in Situ Hybridization Evaluation of c-erbB-2 Gene Amplification and Chromosomal Anomalies in Bladder Cancer¹

Departments of Urology [J-i. O., Y. M., H. U., K. F., K. M., M. H., Y. K.] and Internal Medicine [Y. T.], Yokohama City University School of Medicine, Yokohama 236-0004, Japan

Oncogene amplification and chromosomal anomalies are found in many solid tumors and are often associated with aggressiveness of cancer. We evaluated the frequency and the role of c-erbB-2 gene amplification, relative increase in c-erbB-2 gene copy number, and gain of chromosome 17 in bladder cancer. A total of 29 bladder cancer specimens were examined using fluorescence in situ hybridization (FISH). Dual labeling hybridization with a directly labeled centromere probe for chromosome 17 together with a probe for the c-erbB-2 locus was performed. c-erbB-2 gene amplification was found in 3.4% (1 of 29) of specimens. Relative increase in c-erbB-2 gene copy number was found in 41.4% (12 of 29) of specimens and was significantly associated with tumor grade (P = 0.044 by Fisher’s exact test). Gain of chromosome 17 was identified in 65.5% (19 of 29) of specimens and was significantly associated with tumor grade (P = 0.002 by Fisher’s exact test) and tumor stage (P = 0.003 by Fisher’s exact test). Our results suggest that c-erbB-2 gene amplification, relative increase in c-erbB-2 gene copy number, and gain of chromosome 17 may play important roles in the development and progression of bladder cancers. Moreover, the use of c-erbB-2 amplification, relative increase in c-erbB-2 gene copy number, and gain of chromosome 17 using FISH, together with tumor grade and stage, may provide a more useful clinical indicator in bladder cancer.

This article has been cited by other articles:

				S. Simonetti, R. Russo, G. Ciancia, V. Altieri, G. De Rosa, and L. Insabato Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17 International Journal of Surgical Pathology, June 1, 2009; 17(3): 198 - 205. [Abstract] [PDF]

				S Schwarz, M Rechenmacher, T Filbeck, R Knuechel, H Blaszyk, A Hartmann, and G Brockhoff Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions J. Clin. Pathol., March 1, 2008; 61(3): 272 - 277. [Abstract] [Full Text] [PDF]

				M. H.A. Hussain, G. R. MacVicar, D. P. Petrylak, R. L. Dunn, U. Vaishampayan, P. N. Lara Jr, G. S. Chatta, D. M. Nanus, L. M. Glode, D. L. Trump, et al. Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu-Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial J. Clin. Oncol., June 1, 2007; 25(16): 2218 - 2224. [Abstract] [Full Text] [PDF]

				T. W. Wong, F. Y. Lee, C. Yu, F. R. Luo, S. Oppenheimer, H. Zhang, R. A. Smykla, H. Mastalerz, B. E. Fink, J. T. Hunt, et al. Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling. Clin. Cancer Res., October 15, 2006; 12(20): 6186 - 6193. [Abstract] [Full Text] [PDF]

				B. E. Nicholson, H. F. Frierson, M. R. Conaway, J. M. Seraj, M. A. Harding, G. M. Hampton, and D. Theodorescu Profiling the Evolution of Human Metastatic Bladder Cancer Cancer Res., November 1, 2004; 64(21): 7813 - 7821. [Abstract] [Full Text] [PDF]

				T. T. Junttila, M. Laato, T. Vahlberg, K.-O. Soderstrom, T. Visakorpi, J. Isola, and K. Elenius Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients Clin. Cancer Res., November 1, 2003; 9(14): 5346 - 5357. [Abstract] [Full Text] [PDF]